In October 2018, the FH Foundation, at its annual Global Summit honored Roger Williams MD to commemorate the twentieth anniversary of publication of the World Health Organization (WHO) Consultation on familial hypercholesterolemia (FH), the most common genetic disorder causing premature atherosclerotic cardiovascular disease, and underscore continued gaps in identification and care. (1) FH, with a prevalence of about 1:220-250 worldwide, causes lifelong elevated levels of low-density lipoprotein cholesterol (LDL-c).

We would like to invite you to participate in the Patient Organisation Advisory Board Meeting concerning Heart Failure (HF) organised by Boehringer Ingelheim RCV GmbH & Co KG, which will be held online due to the current COVID-19 situation.

Introduction: The lipid lowering therapy has become one of the basic elements of the cardiovascular prevention and also the attainment of the target levels recommended by the guidelines has an intensified importance in case of patients after acute coronary syndrome (ACS), but it is well known that all over the world this doesn’t reach an acceptable level.

We hope this message finds you well. As promised we would like to officially follow up on our FH Europe Network meeting 2019 in Bucharest. Once again a big thank you to the FOBAC team, speakers and sponsors for their help in organizing this incredible event.

Dear FH Patients!

The following positive information about the domestic support possibility of PCSK9 inhibitors can be shared.